Allergan, Inc.

Hongwen Ma Rivers

Michelle H Luu

Lon T Spada

Wendy M Blanda

Robert T Lyons

John T Trogden

David A Marsh

Michelle Luu

Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.

Autoclavable suspensions of cyclosporin A Form 2

The present invention provides an ocular implant of siRNA complexed with a transfection agent such as cationic lipids and short cell penetration peptides, wherein the complex is associated with a biocompatible polymer. The biocompatible polymer includes a polymeric matrix configured to release the complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.

Sustained release siRNA for ocular drug delivery

An ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein the complex is associated with a biocompatible polymer is described. The biocompatible polymer comprises a polymeric matrix configured to release the complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.

Biocompatible intraocular drug delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

Growing community of inventors

San Marcos, CA, United States of America

Hongwen Ma Rivers